ZEJULA (Niraparib): Important update for the maintenance treatment in relapsed ovarian cancer in the second line or higher settings (2L+)

A Dear Healthcare Professional Letter has been issued by GlaxoSmithKline Pte Ltd to inform healthcare professionals of the updated overall survival (OS) data from the ENGOT-OV16/NOVA study, a Phase III trial which evaluated the efficacy and safety of niraparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. The OS results indicate a possible OS detriment to patients in the overall non-gBRCAmut cohort and to patients in the non-gBRCAmut/HRDpos subgroup who received niraparib maintenance in this setting, as compared to placebo. Healthcare professionals are advised to share the information in this letter with relevant healthcare personnel and patients under their supervision, so that patients can also make an informed decision regarding the use of niraparib in this setting. This recommendation does not apply to the first line ZEJULA indication. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

23 Dec 2022

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.